VERA · Vera Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $86.01M | - | $56.47M | $58.20M | $41.28M | - | $40.31M | $29.31M | $23.20M | - |
| SG&A | $39.12M | - | $27.46M | $21.95M | $15.92M | - | $9.49M | $8.03M | $7.91M | - |
| Total Operating Expenses | $125.13M | - | $83.93M | $80.14M | $57.19M | - | $49.80M | $37.34M | $31.11M | - |
| D&A | $140.0K | - | - | - | $11.0K | - | - | - | - | - |
| Operating Income | ($125.13M) | - | ($83.93M) | ($80.14M) | ($57.19M) | - | ($49.80M) | ($37.34M) | ($31.11M) | - |
| Interest Expense | $1.82M | - | $1.96M | $1.91M | $1.91M | - | $1.94M | $1.91M | $1.91M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($121.03M) | - | ($80.29M) | ($76.53M) | ($51.69M) | - | ($46.63M) | ($33.71M) | ($28.38M) | - |
| EPS - Basic | ($1.69) | - | ($1.26) | ($1.20) | ($0.81) | - | ($0.85) | ($0.62) | ($0.56) | - |
| EPS - Diluted | ($1.69) | - | ($1.26) | ($1.20) | ($0.81) | - | ($0.85) | ($0.62) | ($0.56) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $114.35M | $354.73M | $57.77M | $49.12M | $55.09M | $92.65M | $27.26M | $25.09M | $69.11M | $45.68M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $13.91M | $21.90M | $17.95M | $13.16M | $9.26M | $7.67M | $4.60M | $4.66M | $5.21M | $11.12M |
| Current Assets | $615.80M | $728.88M | $511.31M | $571.35M | $606.08M | $651.22M | $364.13M | $394.75M | $416.37M | $172.02M |
| Total Assets | $621.74M | $734.73M | $517.50M | $578.53M | $610.17M | $655.68M | $368.56M | $397.29M | $419.36M | $175.55M |
| Current Liabilities | $45.15M | $53.45M | $41.88M | $33.55M | $21.89M | $25.37M | $26.46M | $18.42M | $14.54M | $22.30M |
| Long-term Debt | $75.03M | $74.84M | $74.65M | $74.46M | $50.91M | $50.69M | $50.47M | $50.26M | $50.07M | $49.88M |
| Total Liabilities | $122.04M | $130.21M | $118.62M | $110.25M | $75.17M | $78.53M | $79.50M | $69.42M | $65.81M | $73.86M |
| Stockholders' Equity | $499.70M | $604.52M | $398.88M | $468.28M | $535.00M | $577.15M | $289.06M | $327.87M | $353.54M | $101.69M |
| Retained Earnings | ($881.90M) | ($760.87M) | ($669.77M) | ($589.48M) | ($512.94M) | ($461.25M) | ($417.82M) | ($371.19M) | ($337.49M) | ($309.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($106.50M) | - | - | - | ($54.41M) | - | - | - | ($33.83M) | - |
| Investing Cash Flow | ($137.82M) | - | - | - | $15.32M | - | - | - | ($219.29M) | - |
| Financing Cash Flow | $3.94M | - | - | - | $1.53M | - | - | - | $276.54M | - |
| CapEx | $23.0K | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($106.52M) | - | - | - | ($54.41M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.88 | - | - | - | 1.05 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.5% | - | -15.5% | -13.2% | -8.5% | - | -12.7% | -8.5% | -6.8% | - |
| Return on equity | -24.2% | - | -20.1% | -16.3% | -9.7% | - | -16.1% | -10.3% | -8.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 13.64 | 13.64 | 12.21 | 17.03 | 27.68 | 25.67 | 13.76 | 21.43 | 28.63 | 7.71 |
| Quick ratio | 13.64 | 13.64 | 12.21 | 17.03 | 27.68 | 25.67 | 13.76 | 21.43 | 28.63 | 7.71 |
| Cash ratio | 2.53 | 6.64 | 1.38 | 1.46 | 2.52 | 3.65 | 1.03 | 1.36 | 4.75 | 2.05 |
| Leverage | ||||||||||
| Debt / Equity | 0.15 | 0.12 | 0.19 | 0.16 | 0.10 | 0.09 | 0.17 | 0.15 | 0.14 | 0.49 |
| Debt / Assets | 0.12 | 0.10 | 0.14 | 0.13 | 0.08 | 0.08 | 0.14 | 0.13 | 0.12 | 0.28 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -68.6x | - | -42.8x | -41.9x | -30.0x | - | -25.7x | -19.5x | -16.3x | - |
| Equity multiplier | 1.24 | 1.22 | 1.30 | 1.24 | 1.14 | 1.14 | 1.28 | 1.21 | 1.19 | 1.73 |
| Liabilities / Assets | 0.20 | 0.18 | 0.23 | 0.19 | 0.12 | 0.12 | 0.22 | 0.17 | 0.16 | 0.42 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.8x | - | 4.7x | 3.2x | 2.9x | - | 8.4x | 6.0x | 6.2x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -118.8% | - | -68.5% | -114.6% | -83.8% | - | -128.9% | -70.0% | 0.5% | - |
| Net income growth (YoY) | -134.1% | - | -72.2% | -127.0% | -82.1% | - | -132.0% | -67.2% | 5.6% | - |
| EPS growth (YoY) | -108.6% | - | -48.2% | -93.5% | -44.6% | - | -88.9% | -34.8% | 21.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -95.8% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -6.6% | 4.7% | 38.0% | 42.8% | 51.3% | 467.6% | 133.7% | 133.3% | 124.2% | 32.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vera Therapeutics against the 5 most active filers in the same SIC group.